On the stock market since 2022, it operates in the world of health and science. It has 110 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (-1% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
An investor who bought at the very peak is down 84% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $34.6M a year. A small number, but proof the product has real buyers.
A loss of $5.7M against $34.6M in annual sales. And on top of that, sales fell from the year before.
Over the last 12 months, executives reported 48 sells against just 3 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, LFLY sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: LFLY is a high-risk stock — not yet profitable, and its future rides on its product catching on.